Trogarzo drīz nāks pie pacientiem
Apskatīt komentārus (0)


31.07.2019

---

Eiropas Zāļu aģentūras (EMA) Cilvēkiem paredzēto zāļu komiteja (CHMP) rekomendējusi dot atļauju mārketingam, tas ir, ļaut tirgot Trogarzo (ibalizumabum), kas paredzēts to pacientu ārstēšanai, kuriem ir liela noturība pret zālēm HIV-1 infekcijas ārstēšanai.
Ibalizumabs – pirmais antiretrovīrusu preparāts ar jaunu darbības mehānismu, ir monoklonālā antiviela, kas saistās ar CD4 receptoriem, neļaujot HIV iekļūt šūnās – mērķos, T-limfocitos. Šo preparātu pārdos 200 mg iepakojumā kā koncentrātu šķīduma pagatavošanai. Zāles paredzētas lietošanai kopā ar citiem antriretrovīrusu preparātiem pieaugušajiem, kam ir liela noturība (rezistence) pret HIV-1 infekcijas zālēm un kuriem citu pretvīrusu preparātu shēmu iedarbība izrādījusies neefektīva.
Preparāts jālieto infūzijās vēnā. Tā šķaidīšanai jāizmanto 0,9% nātrija hlorīds. Saskaņā ar ražotāja instrukciju, pirmā deva rekomendēta 2000 mg, pēc tam katras nākamās divas nedēļas jāievada atbalstošā deva 800 mg.
***************************
Source: EMA | «Trogarzo» | https://www.ema.europa.eu/en/medicines/human/summaries-opinion/trogarzo |
On 25 July 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Trogarzo, intended for the treatment of HIV infection. The applicant for this medicinal product is Theratechnologies International Limited.
Trogarzo will be available as 200 mg concentrate for solution for infusion. The active substance of Trogarzo is ibalizumab, a monoclonal antibody (ATC code: J05AX23) that binds to a conformational epitope located primarily on domain 2 of the CD4 receptor, inhibiting HIV entry into target cells.
The benefits with Trogarzo are that it can be used as part of a suppressive antiretroviral regimen for patients who cannot be adequately treated with other approved medicines due to extensive viral resistance. The most common side effects are diarrhoea, vomiting, rash, and dizziness. Some cases of immune reconstitution inflammatory syndrome have been reported.
The full indication is:
"Trogarzo, in combination with other antiretroviral(s), is indicated for the treatment of adults infected with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen."
It is proposed that Trogarzo should be prescribed by physicians experienced in the treatment of HIV disease.
Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.